Alleviant Medical


Congestive heart failure affects 6M people in the US, accounts for over $35B in annual spending, and over 1M hospitalizations each year. Existing therapies afford some clinical benefit, but in many cases are ineffective at relieving symptoms or reducing hospital admissions. Many patients remain severely short of breath with very limited quality of life, and despite best medical therapy, 50% of all heart failure patients die within 5 years of diagnosis.

Alleviant medical is focused on developing a novel minimally-invasive device to relieve patient symptoms, improve functional mobility and reduce the frequency of hospital admissions. Their proprietary, single-use transcatheter system enables cardiologists to decompress the heart’s left atrium which is the key driver of heart failure symptoms and hospitalizations. This treatment is expected to lift the burden of heart failure by improving patient symptoms and quality of life, reducing reliance on costly medications and decreasing hospitalization rates.

To date, Alleviant Medical has developed a fully-functional prototype and performed two large animal studies. The company is currently seeking $1.5M in seed financing to transition device development from functional prototype to finalized design; complete 8-10 large animal studies; and execute an FDA pre-submission meeting over the next 12 months.

Company News

Alleviant Medical Announces Presentation of Clinical Data at American College of Cardiology and EuroPCR Conferences

DateMay 17, 2021
Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved ejection fraction (HFpEF).
Read More →

Alleviant Medical Receives Breakthrough Device Designation From FDA for Transcatheter Technology

DateJan 25, 2021
The technology offers a no-implant interatrial shunt therapy for patients suffering from heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) who remain symptomatic despite optimal guideline directed medical therapy.
Read More →

Alleviant Medical completes $6.5m offering

DateMay 19, 2020
Congestive heart failure treatment developer Alleviant Medical filed an SEC Form D to confirm the sale of $6.5 million in an equity offering. The Austin, Texas-based company reached its total offering amount of $6.5 million after making the first sale in the new notice on May 1. It had no intention of letting the offering last longer than one year and did not make it in connection with a business transaction.
Read More →

Congestive heart failure device dev Alleviant Medical raises $1m

DateMar 30, 2018
Alleviant Medical has raised $1.1 million in a new round of debt and options financing, according to an SEC filing posted this week. Money in the round came from 15 unnamed sources, according to the SEC filing, with the first sale recorded on December 19 last year.

Texas Medical Center Announces $25 Million TMC Venture Fund

DateNov 8, 2017
The Texas Medical Center, the largest medical complex in the world, today announced the TMC Venture Fund, a $25 million initiative designed to support technologies and early-stage companies to flourish in Houston’s health care ecosystem and further the TMC’s mission to advance health, education and research.